Research company Ascelia Pharma announces that a peer-reviewed study on Orviglance has been published in the Journal of Magnetic Resonance Imaging. The study addresses pharmacokinetics and pharmacodynamics following a single oral dose of the manganese-based MRI contrast agent in adults with and without impaired liver function.
According to the company, the publication contributes to the evidence supporting Orviglance as a contrast agent for liver imaging.
